Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

无容量 医学 中止 肺癌 免疫疗法 肿瘤科 化疗 内科学 癌症
作者
Matteo Giaj Levra,François-Emery Cotté,Romain Corre,C. Calvet,Anne-Françoise Gaudin,John R. Penrod,V. Grumberg,B. Jouaneton,R. Jolivel,Jean‐Baptiste Assié,C. Chouaïd
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:140: 99-106 被引量:94
标识
DOI:10.1016/j.lungcan.2019.12.017
摘要

Abstract

Objectives

Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolumab and on the interest of a second course of immunotherapy after nivolumab discontinuation. The aims of this study were to describe treatment pathways following nivolumab discontinuation and to describe survival following retreatment with immunotherapy.

Materials and methods

The analysis includes all patients with NSCLC recorded in a national hospital database, starting nivolumab in 2015-2016. Nivolumab treatment was considered discontinued if ≥3 infusions were missed. Patients starting a second course of PD-1 inhibitor following nivolumab discontinuation were analysed according to the duration of their initial nivolumab treatment course.

Results

10,452 patients were included (71 % men; mean age: 63.8 ± 9.6 years; squamous histology: 44 %). Median nivolumab treatment duration was 2.8 months [IQR :1.4–6.9]. Median OS was 11.5 months [95 %CI: 11.1–11.9]; 5118 (53.4 %) patients received post nivolumab therapy lines: 1517 (29.6 %) of these received a second course of PD-1 inhibitor, either after a treatment-free interval (resumption: n=1127) or after intervening chemotherapy (rechallenge: n=390). Median OS after nivolumab discontinuation was 15.0 months [13.9–16.7] in the resumption group and 18.4 months [14.8–21.9] in the rechallenge group. Median OS was significantly longer in patients with an initial nivolumab treatment duration ≥3 months.

Conclusion

In this real-world setting, outcome after retreatment with a PD-1 inhibitor following a first course of nivolumab was significantly better in patients with a longer duration of initial nivolumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明理小凝完成签到 ,获得积分10
刚刚
091完成签到 ,获得积分10
刚刚
xliang233完成签到 ,获得积分10
1秒前
小潘完成签到 ,获得积分10
3秒前
天天天才完成签到,获得积分10
4秒前
完美世界应助able采纳,获得10
5秒前
辛苦科研人完成签到 ,获得积分10
6秒前
慕青应助xiaowan采纳,获得10
8秒前
魏凡之完成签到 ,获得积分10
9秒前
12秒前
13秒前
fuguier发布了新的文献求助10
14秒前
16秒前
zsk1122完成签到,获得积分10
18秒前
荔枝发布了新的文献求助10
18秒前
lyy完成签到 ,获得积分10
19秒前
22秒前
myuniv完成签到,获得积分10
22秒前
专注鸵鸟完成签到,获得积分10
22秒前
专注之双完成签到,获得积分10
23秒前
Zircon完成签到 ,获得积分10
24秒前
Much完成签到 ,获得积分10
25秒前
25秒前
充电宝应助颠覆乾坤采纳,获得10
26秒前
27秒前
无花果应助pz采纳,获得10
27秒前
zheng完成签到 ,获得积分10
29秒前
量子星尘发布了新的文献求助10
30秒前
星辰大海应助荔枝采纳,获得10
30秒前
LJL发布了新的文献求助10
31秒前
meng发布了新的文献求助10
31秒前
无私的颤完成签到,获得积分10
31秒前
lucky完成签到 ,获得积分10
32秒前
Zel博博完成签到,获得积分10
32秒前
谷粱诗云完成签到,获得积分10
32秒前
yar应助myuniv采纳,获得10
32秒前
xc完成签到 ,获得积分10
33秒前
33秒前
干净的天与完成签到,获得积分10
33秒前
哈基米德应助毅诚菌采纳,获得10
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022